PT1362600E - Topical use of nf-kb decoys for treating atopic dermatitis - Google Patents

Topical use of nf-kb decoys for treating atopic dermatitis Download PDF

Info

Publication number
PT1362600E
PT1362600E PT02711351T PT02711351T PT1362600E PT 1362600 E PT1362600 E PT 1362600E PT 02711351 T PT02711351 T PT 02711351T PT 02711351 T PT02711351 T PT 02711351T PT 1362600 E PT1362600 E PT 1362600E
Authority
PT
Portugal
Prior art keywords
decoy
decoys
stat
atopic dermatitis
topical use
Prior art date
Application number
PT02711351T
Other languages
Portuguese (pt)
Inventor
Ryuichi Morishita
Motokuni Aoki
Toshio Ogihara
Yasufumi Kaneda
Hiroshige Nakamura
Original Assignee
Anges Mg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges Mg Inc filed Critical Anges Mg Inc
Publication of PT1362600E publication Critical patent/PT1362600E/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys

Abstract

A pharmaceutical composition for performing treatment against a skin disease, the pharmaceutical composition comprising at least one decoy and a pharmaceutically acceptable carrier. The at least one decoy may be selected from the group consisting of an NF-ºB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The at least one decoy may be an oligonucleotide including at least two decoys bonded to each other, the at least two decoys being selected from the group consisting of an NF-ºB decoy, a STAT-1 decoy, a GATA-3 decoy, a STAT-6 decoy, an AP-1 decoy and an Ets decoy. The skin disease may be atopic dermatitis, psoriasis vulgaris, contact dermatitis, keloid, bedsore, ulcerative colitis, orCrohn's disease.
PT02711351T 2001-02-20 2002-02-06 Topical use of nf-kb decoys for treating atopic dermatitis PT1362600E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001044350 2001-02-20

Publications (1)

Publication Number Publication Date
PT1362600E true PT1362600E (en) 2008-07-09

Family

ID=18906362

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02711351T PT1362600E (en) 2001-02-20 2002-02-06 Topical use of nf-kb decoys for treating atopic dermatitis

Country Status (11)

Country Link
US (2) US9012417B2 (en)
EP (2) EP1362600B1 (en)
JP (2) JP3778357B2 (en)
AT (1) ATE390938T1 (en)
CY (1) CY1108165T1 (en)
DE (1) DE60225899T2 (en)
DK (1) DK1362600T3 (en)
ES (1) ES2307733T3 (en)
PT (1) PT1362600E (en)
TW (1) TWI308492B (en)
WO (1) WO2002066070A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0732929T3 (en) * 1993-10-29 2008-09-01 Brigham & Womens Hospital Therapeutic use of cis element derivatives in vivo
EP1362600B1 (en) 2001-02-20 2008-04-02 AnGes MG, Inc. TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
DE10148886A1 (en) * 2001-10-04 2003-04-30 Avontec Gmbh Inhibition of STAT-1
WO2004110533A1 (en) * 2003-05-09 2004-12-23 Anges Mg, Inc. Needleless syringe having medical agent accommodated therein
AU2003252493A1 (en) * 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
JPWO2005021045A1 (en) * 2003-08-29 2006-10-26 アンジェスＭｇ株式会社 Gene therapy for skin diseases using needleless syringes
WO2005056020A2 (en) * 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
US8034619B2 (en) * 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
EP1799271A4 (en) * 2004-09-21 2010-05-05 Anesiva Inc Delivery of polynucleotides
WO2006043722A1 (en) 2004-10-22 2006-04-27 Anges Mg, Inc. Chimeric (double) decoy
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20090143319A1 (en) * 2005-06-06 2009-06-04 Angesmg, Inc. Transcription factor decoy
EP1915162A4 (en) * 2005-07-27 2009-08-26 Agency Science Tech & Res Modulators
JPWO2007072909A1 (en) * 2005-12-22 2009-06-04 アンジェスＭｇ株式会社 Novel oligonucleotide and NF-κB decoy comprising the same
WO2007071069A1 (en) * 2005-12-22 2007-06-28 Institut De Cardiologie De Montreal Transcription factor decoy oligodeoxynucleotides having multiple cis elements
JP4602298B2 (en) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 Pharmaceutical formulation
US20100105762A1 (en) 2007-02-16 2010-04-29 Ryuichi Morishita Therapeutic agent for periodontal disease and alveolar bone loss due to surgery
US20080249044A1 (en) * 2007-04-03 2008-10-09 Masaya Tanaka Nucleic acid external skin formulation
EP3199635B1 (en) 2007-05-11 2019-02-06 Adynxx, Inc. Gene expression and pain
CN102046208B (en) * 2008-03-28 2014-07-02 安琪士摩奇株式会社 Composition for external application comprising transcription factor decoy as active ingredient
BR112014027653A2 (en) 2012-05-10 2017-08-08 Adynxx Inc formulations for the release of active ingredients
JP6705807B2 (en) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド Oligonucleotide decoys for treating pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361756A (en) * 1942-03-31 1944-10-31 George W Fiero Ointments and the like
JPS56135416A (en) * 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
US4301145A (en) * 1980-07-28 1981-11-17 Cestari Joseph E Antiseptic skin cream
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
JPH05331066A (en) * 1992-05-25 1993-12-14 Toko Yakuhin Kogyo Kk Composition for treatment of acne vulgaris
DK0732929T3 (en) * 1993-10-29 2008-09-01 Brigham & Womens Hospital Therapeutic use of cis element derivatives in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
EP0793963A4 (en) * 1994-10-24 2001-12-12 Nikken Chemicals Co Ltd Percutaneously administrable preparation
DK0824918T3 (en) * 1995-05-12 2007-06-04 Anges Mg Inc Treatment and prevention of diseases caused by NF-kappa B
EA000841B1 (en) * 1995-11-21 2000-04-24 Ай-Си-Эн ФАРМАСЬЮТИКАЛЗ Antisense oligonucleotides for il-8 and il-8 receptor and method ot treating cancer
WO1999001579A1 (en) * 1997-07-01 1999-01-14 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
JP2001055331A (en) * 1999-06-11 2001-02-27 Toyama Chem Co Ltd Atopic dermatitis medicine
EP1170363B1 (en) * 2000-02-02 2007-11-21 Kaneda, Yasufumi Virus envelope vector for gene transfer
DE10049549A1 (en) * 2000-10-06 2002-05-02 Markus Hecker Inhibitor of the transcription factor IFR-1, useful for treating e.g. transplant rejection and autoimmune disease, reduces expression of CD40
EP1362600B1 (en) 2001-02-20 2008-04-02 AnGes MG, Inc. TOPICAL USE OF NF-kB DECOYS FOR TREATING ATOPIC DERMATITIS
WO2003063911A1 (en) * 2002-02-01 2003-08-07 Anges Mg, Inc. Decoy-containing pharmaceutical compositions and method of using the same
JP4971609B2 (en) 2004-08-27 2012-07-11 アンジェスＭｇ株式会社 Nucleic acid skin preparation
JP2006111591A (en) 2004-10-15 2006-04-27 Anges Mg Inc Preparation for target-specifically delivering nucleic acid medicine inside cell

Also Published As

Publication number Publication date
JP4987022B2 (en) 2012-07-25
EP1362600A4 (en) 2005-09-21
JPWO2002066070A1 (en) 2004-06-17
US20040162251A1 (en) 2004-08-19
DE60225899T2 (en) 2009-04-09
EP1362600B1 (en) 2008-04-02
ATE390938T1 (en) 2008-04-15
JP2009102428A (en) 2009-05-14
EP1690544B1 (en) 2017-09-13
TWI308492B (en) 2009-04-11
EP1362600A1 (en) 2003-11-19
EP1690544A3 (en) 2012-03-07
WO2002066070A1 (en) 2002-08-29
JP3778357B2 (en) 2006-05-24
DE60225899D1 (en) 2008-05-15
ES2307733T3 (en) 2008-12-01
DK1362600T3 (en) 2008-07-28
EP1690544A2 (en) 2006-08-16
US20090105183A1 (en) 2009-04-23
CY1108165T1 (en) 2014-02-12
US9012417B2 (en) 2015-04-21

Similar Documents

Publication Publication Date Title
PT1362600E (en) Topical use of nf-kb decoys for treating atopic dermatitis
WO2002043652A3 (en) Anti-proliferative drugs
WO2001048190A3 (en) Therapeutic uses of lna-modified oligonucleotides
MXPA05002791A (en) Non-sequence complementary antiviral oligonucleotides.
IL136839A0 (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2001042457A3 (en) Uncharged antisense oligonucleotides targeted to bacterial 16s and 23s prnas and their uses
EP1537861A3 (en) Use of aminothiol compounds for the treatment xerostomia caused by therapeutic agents or radiation
CA2265917A1 (en) Method for using oligonucleotides having modified cpg dinucleosides
WO2001081671A3 (en) Methods and fabrics for combating nosocomial infections
EP1576963A3 (en) Use of botulinum toxin in the treatment of pain due to an infection
MXPA03010402A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives.
HK1130422A1 (en) A new use of deferiprone
GB9902555D0 (en) Medicament
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
MY138883A (en) Use of asiatic acid for treatment of cencer
WO1999063978A3 (en) Methods of treating microbial infection and therapeutic formulations therefor
WO2003026563A3 (en) Conjugated anti-psychotic drugs and uses thereof
WO1999041364A3 (en) Compositions and methods for wound healing
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
WO2003099213A3 (en) Method for reducing platelet count
MXPA02010184A (en) Topical formulations for the transdermal delivery of niacin and methods of treating hyperlipidemia.
WO2003103699A8 (en) Use of ramoplanin to treat diseases associated with the use of antibiotics
BR0115881A (en) Use of 6-dimethylaminomethyl-1-phenyl-substituted cyclohexanone compounds for urinary incontinence therapy
AU2003222326A1 (en) Composition for transporting oligonucleotides through the blood brain barrier and their use for treating central nervous system diseases